 TAK-475 lapaquistat acetate inhibits the cholesterol synthesis pathway at a different step than statins acting on squalene synthase rather than 3-hydroxy-3-methylglutaryl coenzyme A; it does not reduce concentrations of isoprenylated intermediates believed to be responsible for the myopathies associated with statin use. 